Optimal treatment of pyoderma gangrenosum

被引:37
|
作者
Gettler, SL [1 ]
Rothe, MJ [1 ]
Grin, C [1 ]
Grant-Kels, JM [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Dept Dermatol MC 6230, Sch Med, Farmington, CT 06030 USA
关键词
D O I
10.2165/00128071-200304090-00002
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The optimal treatment of pyoderma gangrenosum includes a combination of local wound care and systemic medications. Oral and pulse intravenous corticosteroids have traditionally been the most commonly recommended first-line systemic therapies. Cyclosporine, with or without corticosteroids, has more recently emerged as a first-line systemic treatment. A multitude of immunosuppressive and immune-modulating medications, as well as antimicrobial agents with anti-inflammatory properties have also been widely prescribed. Often, it is difficult to achieve control of aggressive cases of pyoderma gangrenosum, necessitating administration of a combination of systemic therapies. Furthermore, patients recalcitrant to one or many medications are frequently reported. Concomitant disease, intolerance to a class of medications, and the patient's response to prior therapies can help guide a practitioner in choosing the optimal treatment of pyoderma gangrenosum.
引用
收藏
页码:597 / 608
页数:12
相关论文
共 50 条
  • [1] Optimal Treatment of Pyoderma Gangrenosum
    Samuel L. Gettler
    Marti J. Rothe
    Caron Grin
    Jane M. Grant-Kels
    [J]. American Journal of Clinical Dermatology, 2003, 4 : 597 - 608
  • [2] Treatment of pyoderma gangrenosum
    Chow, RKP
    Ho, VC
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1996, 34 (06) : 1047 - 1060
  • [3] Treatment of Pyoderma Gangrenosum
    Tan, Marcus G.
    Tolkachjov, Stanislav N.
    [J]. DERMATOLOGIC CLINICS, 2024, 42 (02) : 183 - 192
  • [4] Treatment of pyoderma gangrenosum
    Mekkes, Jan Robert
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [5] Pyoderma Gangrenosum: Treatment Options
    Dissemond, Joachim
    Marzano, Angelo V.
    Hampton, Philip J.
    Ortega-Loayza, Alex G.
    [J]. DRUGS, 2023, : 1255 - 1267
  • [6] Treatment options for pyoderma gangrenosum
    Quist, Sven R.
    Kraas, Luise
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 (01): : 34 - 41
  • [7] Adalimumab treatment for pyoderma gangrenosum
    Heffernan, Michael P.
    Anadkat, Milan J.
    Smith, David I.
    [J]. ARCHIVES OF DERMATOLOGY, 2007, 143 (03) : 306 - 308
  • [8] Multimodal treatment of pyoderma gangrenosum
    Li, V
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P212 - P212
  • [9] Tofacitinib for the Treatment of Pyoderma Gangrenosum
    Kochar, Bharati
    Herfarth, Neel
    Mamie, Celine
    Navarini, Alexander A.
    Scharl, Michael
    Herfarth, Hans H.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (05) : 991 - 993
  • [10] Infliximab for treatment of pyoderma gangrenosum
    Lankarani, K. B.
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 2015, 73 (07): : 357 - 357